ARS Pharmaceuticals Inc (NASDAQ: SPRY) on Monday, plunged -5.06% from the previous trading day, before settling in for the closing price of $14.02. Within the past 52 weeks, SPRY’s price has moved between $5.01 and $18.51.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales slid by -34.76% over the last five years. The company achieved an average annual earnings per share of -2.19%. With a float of $50.84 million, this company’s outstanding shares have now reached $97.15 million.
The firm has a total of 26 workers. Let’s measure their productivity. In terms of profitability, gross margin is 93.97%, operating margin of -2384.0%, and the pretax margin is -1934.75%.
ARS Pharmaceuticals Inc (SPRY) Insider Activity
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of ARS Pharmaceuticals Inc is 47.68%, while institutional ownership is 42.09%. The most recent insider transaction that took place on Dec 06 ’24, was worth 711,615. In this transaction Chief Business Officer of this company sold 50,000 shares at a rate of $14.23, taking the stock ownership to the 136,380 shares. Before that another transaction happened on Dec 05 ’24, when Company’s Chief Business Officer sold 49,640 for $14.13, making the entire transaction worth $701,642. This insider now owns 136,380 shares in total.
ARS Pharmaceuticals Inc (SPRY) Earnings and Forecasts
According to the Wall Street analysts, stocks earnings will be around -2.19% per share during the next fiscal year.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Trading Performance Indicators
ARS Pharmaceuticals Inc (SPRY) is currently performing well based on its current performance indicators. A quick ratio of 12.50 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 504.04.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.51, a number that is poised to hit -0.14 in the next quarter and is forecasted to reach -0.36 in one year’s time.
Technical Analysis of ARS Pharmaceuticals Inc (SPRY)
Analysing the last 5-days average volume posted by the [ARS Pharmaceuticals Inc, SPRY], we can find that recorded value of 0.9 million was better than the volume posted last year of 0.82 million. As of the previous 9 days, the stock’s Stochastic %D was 43.55%. Additionally, its Average True Range was 0.94.
During the past 100 days, ARS Pharmaceuticals Inc’s (SPRY) raw stochastic average was set at 45.86%, which indicates a significant increase from 20.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 59.85% in the past 14 days, which was lower than the 71.97% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.77, while its 200-day Moving Average is $11.29. Now, the first resistance to watch is $14.11. This is followed by the second major resistance level at $14.91. The third major resistance level sits at $15.35. If the price goes on to break the first support level at $12.87, it is likely to go to the next support level at $12.43. Should the price break the second support level, the third support level stands at $11.63.
ARS Pharmaceuticals Inc (NASDAQ: SPRY) Key Stats
Market capitalization of the company is 1.30 billion based on 97,185K outstanding shares. Right now, sales total 30 K and income totals -54,370 K. The company made 2,070 K in profit during its latest quarter, and -19,130 K in sales during its previous quarter.
